Out Of Rhythm: Setmelanotide Lacks Proper Placebo Controls And Has Plenty Of Adverse Events Seeking Alpha, 07 Nov 2019 Rhythm Pharmaceuticals is developing Setmelanotide a drug that targets rare forms of genetic obesity by controlling…